logo

Volitionrx Ltd (VNRX)



Trade VNRX now with
  Date
  Headline
1/4/2016 7:03:59 AM VolitionRx Unveils Grant Of U.S. Patent Entitled "Method For Detecting Nucleosomes
12/8/2015 7:19:26 AM VolitionRx Shows More Than 90% Accuracy For Colorectal Cancer NuQ Blood Test In Completed Prospective Study
11/4/2015 6:39:30 AM VolitionRx Q3 Loss Per Share $0.16 Vs Loss $0.44 Last Year
10/12/2015 7:02:30 AM VolitionRx Announces Publication Of Results From Pancreatic Cancer Study With Lund University In Clinical Epigenetics
9/22/2015 7:14:02 AM VolitionRx Reports First CE Mark For NuQ Blood Assay For Detection Of Colorectal Cancer
8/17/2015 8:05:33 AM VolitionRx Names David Kratochvil CFO, Effective Aug. 17
8/11/2015 6:32:00 AM VolitionRx Q2 Net Loss $1.9 Mln Or $0.10/shr Vs. Net Income $0.8 Mln Or $0.06/shr Last Year
7/6/2015 8:20:09 AM VolitionRx Expands Scientific Advisory Board
5/12/2015 7:51:40 AM VolitionRx Q1 Net Loss $2 Mln Or $0.12/shr Vs. Net Loss $2.2 Mln Or $0.18/shr Last Year
5/8/2015 8:13:51 AM VolitionRx Accelerates Clinical Trial With University Hospital Bonn, Germany
3/5/2015 8:06:30 AM VolitionRx Begins Second Prostate Cancer Pilot Study Assessing Nucleosomics Technology
2/24/2015 8:19:25 AM VolitionRx Acquires Direct Ownership Of Nucleosomics Technology Patent
2/6/2015 8:05:37 AM VolitionRx Prices Public Offering Of 2.475 Mln Shares At $3.75 Per Share
12/17/2014 8:06:52 AM VolitionRx To Begin Study With University Hospital Bonn To Confirm NuQ Test Accuracy In Lung Cancer
7/1/2014 6:31:15 AM VolitionRx Announces Mike O'Connell As CFO